摘要利妥昔单抗(RTX)是一种针对B淋巴细胞表面CD20抗原的单克隆抗体,已成功应用于非霍奇金淋巴瘤和多种系统性自身免疫性疾病的治疗,如类风湿性关节炎、系统性红斑狼疮及肉芽肿性血管炎.近年应用RTX治疗难治性巩膜炎、边缘性角膜溃疡、葡萄膜炎及眼部瘢痕性类天疱疮等免疫相关眼病(OID)日益引起关注.RTX可以控制OID眼部炎症,减少或停止糖皮质激素及其他免疫抑制剂的应用,为难治性、严重威胁视力的OID治疗开辟了新的途径.

abstractsRituximab (RTX) is a monoclonal antibody directed against the CD20 antigen expressed on B cells.It has been successfully employed in the treatment of non-Hodgkin's lymphoma and varied systemic autoimmune diseases such as rheumatoid arthritis,systemic lupus erythematosus,and granulomatosis with polyangiitis.Recently its efficacy in the treatment of ocular inflammatory diseases (OID),including refractory scleritis,peripheral ulcerative keratitis,uveitis,and ocular cicatricial pemphigoid,has aroused more concerns.The literature suggests that RTX may be useful for controlling the inflammation and decreasing or stopping the use of corticosteroids and other immunosuppressants in OID,which may contribute a new treatment alternative in patients with the recalcitrant and sight-threatening forms of OID.This article reviews the clinical application status of RTX in the treatment of OID.